Biological Characterization of Nodal versus Extranodal Presentation of Diffuse Large B-Cell Lymphoma using Immunohistochemistry

Title
Biological Characterization of Nodal versus Extranodal Presentation of Diffuse Large B-Cell Lymphoma using Immunohistochemistry
Author(s)
이경희배성화[배성화]배영경금윤섭[금윤섭]여헌모[여헌모]조희순고성애[고성애]이하영[이하영]윤소연[윤소연]최준혁[최준혁]현명수김민경
Keywords
NON-HODGKINS-LYMPHOMAS; GERMINAL CENTER PHENOTYPE; MYC REARRANGEMENTS; NHL REGISTRY; BIOMARKERS; RITUXIMAB; SUBTYPES; CHEMOTHERAPY; EXPRESSION; SURVIVAL
Issue Date
201110
Publisher
CIG MEDIA GROUP, LP
Citation
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, v.11, no.5, pp.403 - 408
Abstract
We evaluated the relationship between DLBCL clinicopathological features, including expression of B-cell differentiation markers, and primary site. We did not find any differences in the frequencies of GCB and non-GCB subtypes among primary sites and there were no differences in the frequencies of GCB and non-GCB subtypes between patients with primary nodal and primary extranodal DLBCL. Introduction: Diffuse large B cell lymphoma (DLBCL) of primary nodal (PN) or primary extranodal (PEN) origin may differ immunophenotypically, in that PEN lymphoma cells may originate from activated rather than germinal center B (GCB) cells. We evaluated the relationship between DLBCL clinicopathological features, including expression of B-cell differentiation markers, and primary tumor site. Patients and Methods: Expression of CD10, Bcl-6, Bcl-2, and MUM1 was determined in paraffin-embedded tissues from 123 patients with DLBCL. Results: Of the 123 patients with DLBCL, 40 (32.5%) had the GCB and 83 (67.5%) had the non-GCB phenotype. Fifty-one patients (42%) showed disease involvement at PEN sites, including 29 with disease in the gastrointestinal (GI) tract (14 in the stomach, 15 in the intestine). Of these 51 patients, 16 (31.4%) were classified with the GCB and 35 (68.5%) with the non-GCB subtype. There were no differences in the frequencies of GCB and non-GCB subtypes among primary sites. Of the 72 patients with PN DLBCL, 22 (31%) had the GCB and 50 (69%) had the non-GCB subtype. There were no differences in the frequencies of GCB and non-GCB subtypes between patients with PN and PEN DLBCL. Although lactate dehydrogenase (LDH) concentration > normal, stage >II, and rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) treatment were independent predictors of overall survival (OS), GCB subtype, and presence of PEN disease failed to predict survival upon multivariate analysis. Conclusion: There was no difference in GCB and non-GCB phenotypes between patients with PN and PEN DLBCLs. Additional studies are needed to further assess molecular differences between the two groups.
URI
http://hdl.handle.net/YU.REPOSITORY/24459http://dx.doi.org/10.1016/j.clml.2011.05.037
ISSN
2152-2650
Appears in Collections:
의과대학 > 내과학교실 > Articles
의과대학 > 병리학교실 > Articles
의과대학 > 진단검사의학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE